These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 30653948)

  • 1. Circulating miR-26a, miR-106b, miR-107 and miR-133b stratify hepatocellular carcinoma patients according to their response to transarterial chemoembolization.
    Ali HEA; Emam AA; Zeeneldin AA; Srour R; Tabashy R; El-Desouky ED; Abd Elmageed ZY; Abdel-Wahab AA
    Clin Biochem; 2019 Mar; 65():45-52. PubMed ID: 30653948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma micoRNA-122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma.
    Kim SS; Nam JS; Cho HJ; Won JH; Kim JW; Ji JH; Yang MJ; Park JH; Noh CK; Shin SJ; Lee KM; Cho SW; Cheong JY
    J Gastroenterol Hepatol; 2017 Jan; 32(1):199-207. PubMed ID: 27194671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival.
    Liu M; Liu J; Wang L; Wu H; Zhou C; Zhu H; Xu N; Xie Y
    PLoS One; 2014; 9(10):e109347. PubMed ID: 25275448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating the pretreatment miRNA expression patterns of advanced hepatocellular carcinoma patients in association with response to TACE treatment.
    El-Halawany MS; Ismail HM; Zeeneldin AA; Elfiky A; Tantawy M; Kobaisi MH; Hamed I; Abdel Wahab AH
    Biomed Res Int; 2015; 2015():649750. PubMed ID: 25811030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The elevated expression of serum glutathione reductase in hepatocellular carcinoma and its role in assessing the therapeutic efficacy and prognosis of transarterial chemoembolization.
    Zheng Q; Xu X; Weng J; Li M; Li B; Cao Y
    Free Radic Biol Med; 2024 Aug; 221():225-234. PubMed ID: 38815771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating MiRNA-373 as a Predictor of Response to Super-selective Transarterial Chemoembolization Bridging Therapy in Hepatocellular Carcinoma Patients Awaiting Liver Transplantation.
    Tork ASE; Kamel AAF; Zaki MA; Abo El-Wafa RAH; El-Assar OS; Ibrahim Abdelkarem OA
    Asian Pac J Cancer Prev; 2023 Jan; 24(1):291-299. PubMed ID: 36708579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma MicroRNA-21, 26a, and 29a-3p as Predictive Markers for Treatment Response Following Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.
    Kim SS; Cho HJ; Nam JS; Kim HJ; Kang DR; Won JH; Kim J; Kim JK; Lee JH; Kim BH; Lee MY; Cho SW; Cheong JY
    J Korean Med Sci; 2018 Jan; 33(1):e6. PubMed ID: 29215815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum TSGF and miR-214 levels in patients with hepatocellular carcinoma and their predictive value for the curative effect of transcatheter arterial chemoembolization.
    Tang L; Zhang XM
    Ann Palliat Med; 2020 Jul; 9(4):2111-2117. PubMed ID: 32762227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
    Wu Y; Fan W; Xue M; Zhong B; Zhang S; Wang Y; Yao W; Zhao Y; Li J
    Oncologist; 2019 Dec; 24(12):e1489-e1495. PubMed ID: 31249138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum miR-21, miR-26a and miR-101 as potential biomarkers of hepatocellular carcinoma.
    Zhuang C; Jiang W; Huang D; Xu L; Yang Q; Zheng L; Wang X; Hu L
    Clin Res Hepatol Gastroenterol; 2016 Sep; 40(4):386-96. PubMed ID: 26669589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of serum HIF-1α change following transarterial chemoembolization in hepatocellular carcinoma.
    Lin ZH; Jiang JR; Ma XK; Chen J; Li HP; Li X; Wu XY; Huang MS; Lin Q
    Clin Exp Med; 2021 Feb; 21(1):109-120. PubMed ID: 33037574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic Changes in Circulating MicroRNA Levels in Liver Cancer Patients Undergoing Thermal Ablation and Transarterial Chemoembolization.
    Zavadil J; Juráček J; Čechová B; Andrašina T; Slabý O; Goldberg N
    Klin Onkol; 2019; 32(Supplementum1):164-166. PubMed ID: 31064190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.
    Martin SP; Fako V; Dang H; Dominguez DA; Khatib S; Ma L; Wang H; Zheng W; Wang XW
    J Exp Clin Cancer Res; 2020 Jun; 39(1):99. PubMed ID: 32487192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible Use of miR-223-3p as a Prognostic Marker in Transarterial Chemoembolization Treatment of Hepatocellular Carcinoma Patients.
    E Abdelaziz H; El-Guendy N; Radwan EM; Sharawi SK; El-Houseini ME; Abdel-Wahab AA
    Asian Pac J Cancer Prev; 2022 Dec; 23(12):4125-4135. PubMed ID: 36579994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization.
    Guo M; Qi F; Rao Q; Sun J; Du X; Qi Z; Yang B; Xia J
    Front Immunol; 2021; 12():754961. PubMed ID: 34691076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-125b Loss Activated HIF1α/pAKT Loop, Leading to Transarterial Chemoembolization Resistance in Hepatocellular Carcinoma.
    Wei X; Zhao L; Ren R; Ji F; Xue S; Zhang J; Liu Z; Ma Z; Wang XW; Wong L; Liu N; Shi J; Guo X; Roessler S; Zheng X; Ji J
    Hepatology; 2021 Apr; 73(4):1381-1398. PubMed ID: 32609900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum microRNA-210 as a predictive biomarker for treatment response and prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    Zhan M; Li Y; Hu B; He X; Huang J; Zhao Y; Fu S; Lu L
    J Vasc Interv Radiol; 2014 Aug; 25(8):1279-1287.e1. PubMed ID: 24935355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating microRNAs panel as a diagnostic tool for discrimination of HCV-associated hepatocellular carcinoma.
    Ali HEA; Abdel Hameed R; Effat H; Ahmed EK; Atef AA; Sharawi SK; Ali M; Abd Elmageed ZY; Abdel Wahab AH
    Clin Res Hepatol Gastroenterol; 2017 Sep; 41(4):e51-e62. PubMed ID: 28750770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 25-OH-vitamin D deficiency identifies poor tumor response in hepatocellular carcinoma treated with transarterial chemoembolization.
    Wu YQ; Fan WZ; Xue M; Guo J; Wei JL; Wang Y; Yao W; Zhao Y; Li JP
    Clin Transl Oncol; 2020 Jan; 22(1):70-80. PubMed ID: 31183764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
    Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
    BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.